3 additional interactor genes were identified that are reported to be targeted by drugs in clinical trials for autoimmune diseases (FGFR3: Masitinib for RA, KCNA3: Dalfampridine for multiple sclerosis, PSMB5: Bortezomib and Ixazomib for autoimmune thrombocytopenic purpura) In order to progress the analysis and validate potential therapeutic targets, genes with available tool compounds were selected that may impact and disrupt the disease network. The gene discussed is KCNA3; the disease is rheumatoid arthritis.